Sergei Chetyrkin
Last active: 3/4/2014


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. A unique covalent bond in basement membrane is a primordial innovation for tissue evolution. Fidler AL, Vanacore RM, Chetyrkin SV, Pedchenko VK, Bhave G, Yin VP, Stothers CL, Rose KL, McDonald WH, Clark TA, Borza DB, Steele RE, Ivy MT, Aspirnauts, Hudson JK, Hudson BG (2014) Proc Natl Acad Sci U S A 111(1): 331-6
    › Primary publication · 24344311 (PubMed) · PMC3890831 (PubMed Central)
  2. Site-specific AGE modifications in the extracellular matrix: a role for glyoxal in protein damage in diabetes. Voziyan P, Brown KL, Chetyrkin S, Hudson B (2014) Clin Chem Lab Med 52(1): 39-45
    › Primary publication · 23492568 (PubMed) · PMC4104777 (PubMed Central)
  3. Inhibition of integrin α2β1 ameliorates glomerular injury. Borza CM, Su Y, Chen X, Yu L, Mont S, Chetyrkin S, Voziyan P, Hudson BG, Billings PC, Jo H, Bennett JS, Degrado WF, Eckes B, Zent R, Pozzi A (2012) J Am Soc Nephrol 23(6): 1027-38
    › Primary publication · 22440900 (PubMed) · PMC3358756 (PubMed Central)
  4. Pyridoxamine protects protein backbone from oxidative fragmentation. Chetyrkin S, Mathis M, Hayes McDonald W, Shackelford X, Hudson B, Voziyan P (2011) Biochem Biophys Res Commun 411(3): 574-9
    › Primary publication · 21763683 (PubMed) · PMC3153140 (PubMed Central)
  5. Glucose autoxidation induces functional damage to proteins via modification of critical arginine residues. Chetyrkin S, Mathis M, Pedchenko V, Sanchez OA, McDonald WH, Hachey DL, Madu H, Stec D, Hudson B, Voziyan P (2011) Biochemistry 50(27): 6102-12
    › Primary publication · 21661747 (PubMed) · PMC3140462 (PubMed Central)
  6. A lentiviral functional proteomics approach identifies chromatin remodeling complexes important for the induction of pluripotency. Mak AB, Ni Z, Hewel JA, Chen GI, Zhong G, Karamboulas K, Blakely K, Smiley S, Marcon E, Roudeva D, Li J, Olsen JB, Wan C, Punna T, Isserlin R, Chetyrkin S, Gingras AC, Emili A, Greenblatt J, Moffat J (2010) Mol Cell Proteomics 9(5): 811-23
    › Primary publication · 20305087 (PubMed) · PMC2871416 (PubMed Central)
  7. Modification of collagen IV by glucose or methylglyoxal alters distinct mesangial cell functions. Pozzi A, Zent R, Chetyrkin S, Borza C, Bulus N, Chuang P, Chen D, Hudson B, Voziyan P (2009) J Am Soc Nephrol 20(10): 2119-25
    › Primary publication · 19608705 (PubMed) · PMC2754111 (PubMed Central)
  8. Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis. Thotala D, Chetyrkin S, Hudson B, Hallahan D, Voziyan P, Yazlovitskaya E (2009) Free Radic Biol Med 47(6): 779-85
    › Primary publication · 19540915 (PubMed) · PMC2739572 (PubMed Central)
  9. Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine. Chetyrkin SV, Mathis ME, Ham AJ, Hachey DL, Hudson BG, Voziyan PA (2008) Free Radic Biol Med 44(7): 1276-85
    › Primary publication · 18374270 (PubMed)
  10. Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Chetyrkin SV, Zhang W, Hudson BG, Serianni AS, Voziyan PA (2008) Biochemistry 47(3): 997-1006
    › Primary publication · 18161948 (PubMed)
  11. Role of microsomal retinol/sterol dehydrogenase-like short-chain dehydrogenases/reductases in the oxidation and epimerization of 3alpha-hydroxysteroids in human tissues. Belyaeva OV, Chetyrkin SV, Clark AL, Kostereva NV, SantaCruz KS, Chronwall BM, Kedishvili NY (2007) Endocrinology 148(5): 2148-56
    › Primary publication · 17289849 (PubMed) · PMC2571913 (PubMed Central)
  12. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Scheinman JI, Voziyan PA, Belmont JM, Chetyrkin SV, Kim D, Hudson BG (2005) Urol Res 33(5): 368-71
    › Primary publication · 16292584 (PubMed)
  13. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Pedchenko VK, Chetyrkin SV, Chuang P, Ham AJ, Saleem MA, Mathieson PW, Hudson BG, Voziyan PA (2005) Diabetes 54(10): 2952-60
    › Primary publication · 16186398 (PubMed)
  14. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Chetyrkin SV, Kim D, Belmont JM, Scheinman JI, Hudson BG, Voziyan PA (2005) Kidney Int 67(1): 53-60
    › Primary publication · 15610227 (PubMed)
  15. Characterization of truncated mutants of human microsomal short-chain dehydrogenase/reductase RoDH-4. Belyaeva OV, Chetyrkin SV, Kedishvili NY (2003) Chem Biol Interact : 279-87
    › Primary publication · 12604214 (PubMed)
  16. Evidence that the human gene for prostate short-chain dehydrogenase/reductase (PSDR1) encodes a novel retinal reductase (RalR1). Kedishvili NY, Chumakova OV, Chetyrkin SV, Belyaeva OV, Lapshina EA, Lin DW, Matsumura M, Nelson PS (2002) J Biol Chem 277(32): 28909-15
    › Primary publication · 12036956 (PubMed)
  17. Further characterization of human microsomal 3alpha-hydroxysteroid dehydrogenase. Chetyrkin SV, Hu J, Gough WH, Dumaual N, Kedishvili NY (2001) Arch Biochem Biophys 386(1): 1-10
    › Primary publication · 11360992 (PubMed)
  18. Characterization of a novel type of human microsomal 3alpha -hydroxysteroid dehydrogenase: unique tissue distribution and catalytic properties. Chetyrkin SV, Belyaeva OV, Gough WH, Kedishvili NY (2001) J Biol Chem 276(25): 22278-86
    › Primary publication · 11294878 (PubMed)
  19. [Transport and metabolism of vitamin A]. Chetyrkin SV (2000) Ukr Biokhim Zh (1999) 72(3): 12-24
    › Primary publication · 11200465 (PubMed)
  20. [Effect of low doses of radiation on vitamin A and E levels in rat liver]. Chetyrkin SV, Chernukhina LA, Porokhniak LA, Donchenko GV, Kuz'menko IV, Klimenko EP (1999) Ukr Biokhim Zh (1999) 71(2): 38-42
    › Primary publication · 10609300 (PubMed)